Promising combo therapy for aggressive brain cancer enters final testing phase

NCT ID NCT06419946

Recruiting now Disease control Sponsor: Vastra Gotaland Region Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether adding lomustine to standard temozolomide chemotherapy improves survival for people with newly diagnosed glioblastoma that has a specific genetic marker (MGMT methylated). About 200 adults aged 18-70 will be randomly assigned to receive either the standard drug alone or the two-drug combination, starting with radiation. Researchers will track survival, tumor progression, side effects, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Temozolomide and lomustine (chemotherapy pills)
What this could lead to: If successful, this combination could extend survival for people with a specific type of glioblastoma, offering a new standard treatment option.
What could go wrong: This is an early-stage Phase 3 trial with only 200 participants. The combination may cause more side effects than standard therapy, and results may not apply to all glioblastoma patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA, IDH-WILDTYPE MGMT-METHYLATED GLIOBLASTOMA

Contacts and locations

Locations

Aarhus University Hospital
RECRUITING

Aarhus, Denmark
Gävle Hospital
RECRUITING

Gävle, Sweden
Haukeland University Hospital
RECRUITING

Bergen, Norway
Kalmar Country Hospital
RECRUITING

Kalmar, Sweden
Karolinska Institutet
ENROLLING_BY_INVITATION

Stockholm, Sweden
Kepler University Hospital
RECRUITING

Linz, Austria
Medizinische Universität Innsbruck
NOT_YET_RECRUITING

Innsbruck, Austria
Norrlands Universitetssjukhus, Umea, Sweden
RECRUITING

Umeå, Sweden
Oslo University Hospital
RECRUITING

Oslo, Norway
Ryhov County Hospital
RECRUITING

Jönköping, Sweden
Sahlgrenska University Hospital
RECRUITING

Gothenburg, Sweden
Skåne University Hospital
NOT_YET_RECRUITING

Lund, Sweden
Sorlandet Sykehus
RECRUITING

Kristiansand, Norway
St Olavs Hospital
NOT_YET_RECRUITING

Trondheim, Norway
Stavanger University Hospital
NOT_YET_RECRUITING

Stavanger, Norway
Sundsvall Hospital
ENROLLING_BY_INVITATION

Sundsvall, Sweden
University Hospital Graz
NOT_YET_RECRUITING

Graz, Austria
University Hospital St. Pölten
ENROLLING_BY_INVITATION

Sankt Pölten, Austria
Uppsala University Hospital
RECRUITING

Uppsala, Sweden
Örebro University Hospital
RECRUITING

Örebro, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.